A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity

Growth Factors

Volumn 32, Issue 6, 2014, Pages 223-235

  Tomasevic, Nenad ^a   Luehrsen, Kenneth ^a   Baer, Mark ^a   Palath, Varghese ^a   Martinez, David ^a   Williams, Jason ^a   Yi, Christina ^a   Sujatha Bhaskar, Swathi ^a   Lanke, Rohini ^a   Leung, John ^a   Ching, Wendy ^a   Lee, Andreia ^a   Bai, Lu ^a   Yarranton, Geoffrey ^a   Bebbington, Christopher ^a  

^a KaloBios Inc   (United States)

Author keywords

ADCC; EphA3; Humaneered; Leukemia; Non fucosylated

Indexed keywords

CD16 ANTIGEN; CD16A ANTIGEN; EPHRIN A5; EPHRIN RECEPTOR A3; FUCOSYLTRANSFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M111A4; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BONE MARROW DERIVED MONONUCLEAR CELL; CELL KILLING; CONTROLLED STUDY; EFFECTOR CELL; FUCOSYLATION; HEAVY CHAIN; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RAT;

CRICETULUS GRISEUS;

EID: 84918793763     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.984808     Document Type: Article

References (41)

1. Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, et al. 2012. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 11:359-372
2. Boyd AW, Ward LD, Wicks IP, Simpson RJ, Salvaris E, Wilks A, Welch K, et al. 1992. Isolation and characterization of a novel receptor-Type protein tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem 267:3262-3267
3. Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC, Pan C, et al. 2010. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother: CII 59:257-265
4. Charmsaz S, Boyd AW. 2013. Expression and function of the Eph receptor family in leukemia and hematopoietic malignancies: Prospects for targeted therapies. J Leukemia1:107 [Online] Available from: http://esciencecentral.org/journals/expression-Andfunction-of-The-eph-receptor-family-in-leukemia-And-hematopoieticmalignancies-prospects-for-Targeted-Therapies-2329-6917.1000107 .php?aid'12277 [Accessed 17 Sep 2014
5. Cheng HJ, Flanagan JG. 1994. Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases. Cell 79:157-168
6. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. 2000. Identification of a tumor-specific shared antigen Derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 60:4855-4863
7. Cilloni D, Arruga F, Carturan S, Messa F, Pradotto M, Defilippi I, Pautasso M, et al. 2008. EphA3 kinase is constitutively activated in chronic myeloid leukaemia during progression to accelerated and blast crisis and it could represent a new molecular target. Blood 112:ASH Abstract:1092
8. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23: 238-248
9. Davy A, Gale NW, Murray EW, Klinghoffer RA, Soriano P, Feuerstein C, Robbins SM. 1999. Compartmentalized signaling by GPI-Anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 13:3125-3135
10. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, et al. 2001. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98:771-780
11. Gallarda BW, Bonanomi D, Muller D, Brown A, Alaynick WA, Andrews SE, Lemke G, et al. 2008. Segregation of axial motor and sensory pathways via heterotypic trans-Axonal signaling. Science 320:233-236
12. Guan M, Liu L, Zhao X, Wu Q, Yu B, Shao Y, Yang H, et al. 2011. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin Lymphoma Myeloma Leukemia 11: 50-53
13. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, et al. 2004. Differential gene expression of Eph receptors and ephrins in benign human issues and cancers. Clin Chem 50:490-499
14. Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. mAbs 2:256-265
15. Holder N, Klein R. 1999. Eph receptors and ephrins: Effectors of morphogenesis. Development 126:2033-2044
16. Holland SJ, Peles E, Pawson T, Schlessinger J. 1998. Cell-contactdependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase beta. Curr Opin Neurobiol 8:117-127
17. Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10
18. Janes PW, Nievergall E, Lackmann M. 2012. Concepts and consequences of Eph receptor clustering. Seminars Cell Dev Biol 23:43-50
19. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, et al. 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-Amplified breast cancer. Cancer Res 70: 4481-4489
20. Keane N, Freeman C, Swords R, Giles FJ. 2012. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hemat 5:325-340
21. Lackmann M, Mann RJ, Kravets L, Smith FM, Bucci TA, Maxwell KF, Howlett GJ, et al. 1997. Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J Biol Chem 272:16521-16530
22. Lawrenson I, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M. 2002. Ephrin-A5 induces rounding, blebbing and deadhesion of EphA3-expressing 293T and melanoma cells by Crkll and Rho-demediated signalling. J Cell Sci 115:1059-1072
23. Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, et al. 2009. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood 114:1585-1595
24. Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP, Malpas JS. 2004. s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hemat J 5: 247-254
25. Lu CH, Yang ZX, Liang Z, Huang ZZ, ZHang HT, Li J, Tao KS, Xie BZ. 2013. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Rep 30:2179-2186
26. McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C. 1999. Oncogenic homeodomain transcription factor E2APbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 96:11464-11469
27. Mosch B, Reissenweber B, Neuber C, Pietzsch J. 2010. Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis. J Oncol 2010:135285
28. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796
29. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibodydependent cellular cytotoxicity induction at lower antigen Density. Clin Cancer Res 11:2327-2336
30. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, et al. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336:1239-1249
31. Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, et al. 2009. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: An inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19:126-134
32. Smith LM, Walsh PT, Rudiger T, Cotter TG, Mc Carthy TV, Marx A, O'Connor R. 2004a. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp Cell Res 292:295-303
33. Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, et al. 2004b. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J Biol Chem 279: 9522-9531
34. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. 2007. A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 302:66-79
35. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, et al. 2005. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23: 474-481
36. Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, et al. 2014. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470-4481
37. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-Targeting reagents. Cancer Res 65:6745-6754
38. Wicks IP, Wilkinson D, Salvaris E, Boyd AW. 1992. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci USA 89:1611-1615
39. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. 1997. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Investig 100:1059-1070
40. Xi HQ, Zhao P. 2011. Clinicopathological Significance and Prognostic Value of EphA3 and CD133 Expression in Colorectal Carcinoma. J Clin Pathol 64:498-503
41. Xi HQ, Wu XS, Wei B, Chen L 2012. Aberrant expression of EphA3 in gastric carcinoma: Correlation with tumor angiogenesis and survival. J Gastroenterol 47:785-794